BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1494 related articles for article (PubMed ID: 26133582)

  • 1. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
    Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations in (18)F-FDG uptake in breast cancer depending on PET/CT acquisition position.
    Lee JH; Jeon TJ; Ahn SG; Jeong J; Seok JW; Ryu YH
    Clin Radiol; 2016 Jan; 71(1):86-91. PubMed ID: 26646369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
    Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
    J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.
    Teixeira SC; Koolen BB; Vogel WV; Wesseling J; Stokkel MP; Vrancken Peeters MJ; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Clin Nucl Med; 2016 Apr; 41(4):e181-6. PubMed ID: 26704731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delineation of small mobile tumours with FDG-PET/CT in comparison to pathology in breast cancer patients.
    Hapdey S; Edet-Sanson A; Gouel P; Martin B; Modzelewski R; Baron M; Berghian A; Forestier-Lebreton F; Georgescu D; Picquenot JM; Gardin I; Dubray B; Vera P
    Radiother Oncol; 2014 Sep; 112(3):407-12. PubMed ID: 25216573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of
    Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
    AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.
    Whisenant JG; Williams JM; Kang H; Arlinghaus LR; Abramson RG; Abramson VG; Fakhoury K; Chakravarthy AB; Yankeelov TE
    Tomography; 2020 Jun; 6(2):170-176. PubMed ID: 32548293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Added value of prone position technique for PET-TAC in breast cancer patients].
    Vidal-Sicart S; Aukema TS; Vogel WV; Hoefnagel CA; Valdés-Olmos RA
    Rev Esp Med Nucl; 2010; 29(5):230-5. PubMed ID: 20624663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the detection of small lesions using a state-of-the-art time-of-flight PET/CT system and small-voxel reconstructions.
    Koopman D; van Dalen JA; Lagerweij MC; Arkies H; de Boer J; Oostdijk AH; Slump CH; Jager PL
    J Nucl Med Technol; 2015 Mar; 43(1):21-7. PubMed ID: 25613334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR.
    Rasmussen JH; Fischer BM; Aznar MC; Hansen AE; Vogelius IR; Löfgren J; Andersen FL; Loft A; Kjaer A; Højgaard L; Specht L
    Br J Radiol; 2015 Apr; 88(1048):20140655. PubMed ID: 25634069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test-Retest Variability in Lesion SUV and Lesion SUR in
    Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
    J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
    Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
    Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
    Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
    Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.